DLL3 and small cell lung carcinoma: Similar to its investigations with ADCs and BiTEs, DLL3 has emerged as a promising target for CAR-T cell therapy (Figure 5) due to its substantial over-expression in SCLC and the absence of cell surface DLL3 in non-malignant cells [93].